Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 studyFranco Locatelli, Cristina Díaz de Heredia, Annie St. Pierre et al.|Blood|2024Cited by 24
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22<sup>+</sup> acute lymphoblastic leukemia: results of the phase IB ITCC-059 trialEdoardo Pennesi, C. Michel Zwaan, Erica Brivio et al.|Haematologica|2024Cited by 18
Ruxolitinib in Pediatric Patients with Treatment-<i>Naïve</i> or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 StudyFranco Locatelli, Cristina Díaz de Heredia, Hyoung Jin Kang et al.|Blood|2022Cited by 11
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059Jen-Hao Wu, Alwin D. R. Huitema, Edoardo Pennesi et al.|Clinical Pharmacokinetics|2024Cited by 6
Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II TrialEdoardo Pennesi, C. Michel Zwaan, Erica Brivio et al.|Blood|2022Cited by 3